Gattlen Christophe, Deftu Alexandru-Florian, Tonello Raquel, Ling Yuejuan, Berta Temugin, Ristoiu Violeta, Suter Marc René
Pain Center, Department of Anesthesiology, Lausanne University Hospital and University of Lausanne (CHUV), Lausanne, Switzerland.
Faculty of Biology and Medicine (FBM), University of Lausanne (UNIL), Lausanne, Switzerland.
Glia. 2020 Oct;68(10):2119-2135. doi: 10.1002/glia.23831. Epub 2020 Mar 27.
Spinal microglia change their phenotype and proliferate after nerve injury, contributing to neuropathic pain. For the first time, we have characterized the electrophysiological properties of microglia and the potential role of microglial potassium channels in the spared nerve injury (SNI) model of neuropathic pain. We observed a strong increase of inward currents restricted at 2 days after injury associated with hyperpolarization of the resting membrane potential (RMP) in microglial cells compared to later time-points and naive animals. We identified pharmacologically and genetically the current as being mediated by Kir2.1 ion channels whose expression at the cell membrane is increased 2 days after SNI. The inhibition of Kir2.1 with ML133 and siRNA reversed the RMP hyperpolarization and strongly reduced the currents of microglial cells 2 days after SNI. These electrophysiological changes occurred coincidentally to the peak of microglial proliferation following nerve injury. In vitro, ML133 drastically reduced the proliferation of BV2 microglial cell line after both 2 and 4 days in culture. In vivo, the intrathecal injection of ML133 significantly attenuated the proliferation of microglia and neuropathic pain behaviors after nerve injury. In summary, our data implicate Kir2.1-mediated microglial proliferation as an important therapeutic target in neuropathic pain.
脊髓小胶质细胞在神经损伤后会改变其表型并增殖,从而导致神经性疼痛。我们首次在神经性疼痛的 spared 神经损伤(SNI)模型中,对小胶质细胞的电生理特性以及小胶质细胞钾通道的潜在作用进行了表征。我们观察到,与后期时间点和未受伤动物相比,损伤后 2 天小胶质细胞内向电流显著增加,且静息膜电位(RMP)发生超极化。我们通过药理学和遗传学方法确定该电流由 Kir2.1 离子通道介导,其在细胞膜上的表达在 SNI 后 2 天增加。用 ML133 和 siRNA 抑制 Kir2.1 可逆转 RMP 超极化,并在 SNI 后 2 天显著降低小胶质细胞的电流。这些电生理变化与神经损伤后小胶质细胞增殖的峰值同时发生。在体外,ML133 在培养 2 天和 4 天后均显著降低了 BV2 小胶质细胞系的增殖。在体内,鞘内注射 ML133 可显著减轻神经损伤后小胶质细胞的增殖和神经性疼痛行为。总之,我们的数据表明 Kir2.1 介导的小胶质细胞增殖是神经性疼痛的一个重要治疗靶点。